REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

Clinical trial NCT05973773 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05973773
Sponsor: Taiho Oncology, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

Start date: 2023-12-18
Primary completion: 2027-05-27
Enrollment: 285

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.